small molecule

SUMAVEL DOSEPRO

SUMATRIPTAN SUCCINATE

Loss of exclusivityNovember 2026latest FDA-listed patent expiry
CompanyENDO OPERATIONS LTD

Drug detail

Brand nameSUMAVEL DOSEPRO
Active ingredientSUMATRIPTAN SUCCINATE
StrengthEQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)
Dosage formINJECTABLE
RouteSUBCUTANEOUS
ModalitySmall molecule
FDA approvalJuly 2009
Marketing statusDISCN

Listed patents

PatentExpiresType
7776007November 2026product
7901385July 2026product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

SUMAVEL DOSEPRO patent cliff — loss of exclusivity November 2026 | CliffBio